Linked Life Data

19766109

Source:http://linkedlifedata.com/resource/pubmed/id/19766109

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2009-10-28
pubmed:abstractText
The triptans, serotonin 5-HT(1B/1D) receptor agonists exemplified by sumatriptan, are a mainstay migraine therapy but have class labeling contraindicating their use in patients with coronary artery disease. Triptans constrict human coronary artery in vitro, and there are case reports of myocardial infarction in patients using sumatriptan. However, preclinical studies with sumatriptan in normal dogs have failed to demonstrate effects on resting coronary flow. Calcitonin gene-related peptide (CGRP) receptor antagonism, exemplified by the prototype CGRP receptor antagonist peptide CGRP(8-37), is a new antimigraine mechanism which also has been reported to have no effect on coronary flow in normal, non-stressed animals. The goal of the present studies was to compare the effects of sumatriptan (10microg/kg/min i.v.) and CGRP(8-37) (30microg/kg/min i.v.) on systemic and coronary hemodynamics in conscious dogs under resting conditions and during myocardial reactive hyperemia following a brief 15s of coronary artery occlusion. Neither CGRP(8-37) nor sumatriptan affected resting coronary flow. However, whereas CGRP(8-37) had no effect on myocardial reactive hyperemic response, sumatriptan reduced peak reactive hyperemic coronary artery blood flow (baseline vs treatment: 75.4+/-12.7 vs 60.0+/-10.3ml/min, P<0.05), reactive hyperemic flow (16.7+/-5.2 vs 11.6+/-3.3ml, P<0.05) and the repayment of coronary blood flow debt following coronary artery occlusion (484+/-76 vs 369+/-57%, P<0.05), indicating an impairment in coronary blood flow reserve. The positive control nitric oxide synthase inhibitor L-NNA (30mg/kg/30min i.v.) likewise significantly attenuated myocardial reactive hyperemic response. These findings provide evidence for a differentiation between CGRP receptor antagonism and triptan effects on coronary vascular function.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1879-0712
pubmed:author
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
623
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
96-102
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19766109-Animals, pubmed-meshheading:19766109-Calcitonin Gene-Related Peptide, pubmed-meshheading:19766109-Catheters, Indwelling, pubmed-meshheading:19766109-Consciousness, pubmed-meshheading:19766109-Coronary Artery Disease, pubmed-meshheading:19766109-Coronary Circulation, pubmed-meshheading:19766109-Coronary Occlusion, pubmed-meshheading:19766109-Cross-Over Studies, pubmed-meshheading:19766109-Dogs, pubmed-meshheading:19766109-Hemodynamics, pubmed-meshheading:19766109-Hyperemia, pubmed-meshheading:19766109-Infusions, Intra-Arterial, pubmed-meshheading:19766109-Migraine Disorders, pubmed-meshheading:19766109-Peptide Fragments, pubmed-meshheading:19766109-Receptors, Calcitonin Gene-Related Peptide, pubmed-meshheading:19766109-Serotonin 5-HT1 Receptor Agonists, pubmed-meshheading:19766109-Serotonin Receptor Agonists, pubmed-meshheading:19766109-Sumatriptan, pubmed-meshheading:19766109-Time Factors
pubmed:year
2009
pubmed:articleTitle
Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.
pubmed:affiliation
WP46-300, Merck Research Laboratories, West Point PA, 19486, USA. joseph_lynch@merck.com
pubmed:publicationType
Journal Article, Comparative Study